Durham Drug Developer BioCryst Pharmaceuticals Set to Buy Presidio Pharmaceuticals

Durham-based drug developer BioCryst Pharmaceuticals is buying San Francisco-based Presidio Pharmaceuticals in an attempt to develop new treatments for hepatitis C.